These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease. Drouvalakis KA; Buchanan RR J Rheumatol; 1998 Feb; 25(2):290-5. PubMed ID: 9489821 [TBL] [Abstract][Full Text] [Related]
24. [Relation of antiphospholipid antibodies to thrombotic phenomena and clinical activity of systemic lupus erythematosus]. Font J; Cervera R; Casals FJ; Bové A; Guerrero A; López-Soto A; Ingelmo M; Urbano-Márquez A Med Clin (Barc); 1988 Mar; 90(12):490-3. PubMed ID: 3134583 [No Abstract] [Full Text] [Related]
26. A simplified platelet factor 3 (PF-3) assay for the rapid detection of platelet isoantibodies and an antiplatelet factor in ATP and SLE. Hirschman RJ; Gralnick HR J Lab Clin Med; 1974 Aug; 84(2):292-7. PubMed ID: 4135594 [No Abstract] [Full Text] [Related]
27. Lupus anticoagulant. A report of 8 cases. Agarwal MB; Agarwal UM J Assoc Physicians India; 1991 Mar; 39(3):243-5. PubMed ID: 1908857 [TBL] [Abstract][Full Text] [Related]
29. [The antiphospholipid antibody syndrome: its pathogenesis and clinico-morphological manifestations]. Zerbino DD; Lukasevich LL; Bilynskaia OA Arkh Patol; 1990; 52(4):65-9. PubMed ID: 2117434 [TBL] [Abstract][Full Text] [Related]
30. [The antiphospholipid antibody syndrome: a new clinical and therapeutic viewpoint in systemic lupus erythematosus]. Bravo-Vargas G; Lavalle-Montalvo C Gac Med Mex; 1988; 124(1-2):39-42. PubMed ID: 3145236 [No Abstract] [Full Text] [Related]
31. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Galli M; Béguin S; Lindhout T; Hemker CH Br J Haematol; 1989 Aug; 72(4):549-55. PubMed ID: 2505834 [TBL] [Abstract][Full Text] [Related]
32. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. Denis-Magdelaine A; Flahault A; Verdy E Haemostasis; 1995; 25(3):98-105. PubMed ID: 7607585 [TBL] [Abstract][Full Text] [Related]
33. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. Rauch J; Tannenbaum M; Tannenbaum H; Ramelson H; Cullis PR; Tilcock CP; Hope MJ; Janoff AS J Biol Chem; 1986 Jul; 261(21):9672-7. PubMed ID: 3733693 [TBL] [Abstract][Full Text] [Related]
34. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Regnault V; Béguin S; Wahl D; de Maistre E; Coenraad Hemker H; Lecompte T Thromb Haemost; 2003 Feb; 89(2):208-12. PubMed ID: 12574797 [TBL] [Abstract][Full Text] [Related]
35. Comparison of two simple tests for the lupus anticoagulant. Exner T Am J Clin Pathol; 1985 Feb; 83(2):215-8. PubMed ID: 3918436 [TBL] [Abstract][Full Text] [Related]
37. The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. Moore GW; Smith MP; Savidge GF Blood Coagul Fibrinolysis; 2003 Apr; 14(3):307-12. PubMed ID: 12695757 [TBL] [Abstract][Full Text] [Related]
38. Studies on phospholipids in the action of a lupus coagulation inhibitor. Exner T; Rickard KA; Kronenberg H Pathology; 1975 Oct; 7(4):319-28. PubMed ID: 1223721 [TBL] [Abstract][Full Text] [Related]
39. Low plasma factor XII activity in patients with systemic lupus erythematosus and a lupus anticoagulant. Matsuda J; Gotoh M Blood Coagul Fibrinolysis; 1997 Jun; 8(4):255-6. PubMed ID: 9199826 [No Abstract] [Full Text] [Related]
40. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies. Viveros ME; Cabiedes J; Reyes E; Cabral AR Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]